Max Robotics — Global Service Robot Directory + US Certification

About

Michiel W. M. van den Brekel is a leading head and neck oncologist whose research bridges surgical innovation, radiobiology, and patient-centered decision-making. His primary contributions lie in the treatment of oropharyngeal cancer, where he has championed the use of transoral robotic surgery (TORS). His landmark 2014 study on the outcome of TORS for stage I–II oropharyngeal cancer (40 citations) established critical benchmarks for this minimally invasive approach, demonstrating its efficacy in preserving function without compromising oncologic control. Beyond the operating room, van den Brekel has made significant strides in radiobiology. He co-authored the 2017 identification of a novel ATM inhibitor that achieves cancer cell-specific radiosensitization (32 citations), a discovery that holds promise for enhancing radiotherapy’s effectiveness while sparing healthy tissue—a key challenge in head and neck cancer care. More recently, he has focused on shared decision-making, leading the development of a patient decision aid for operable oropharyngeal carcinoma, reflecting his commitment to integrating patient values into complex treatment choices. With a career that seamlessly integrates surgical technique, molecular discovery, and patient empowerment, van den Brekel’s work continues to shape how we treat and support individuals with head and neck cancer.